Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 23 of 23 publications.

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):833-42. doi: 10.1080/14796694.2025.2464485

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025 Mar;21(7):843-51. doi: 10.1080/14796694.2025.2463276

Ailawadhi S, Inocencio TJ, Mansfield C, Chintakayala P, Bussberg C, Chi L, Harnett J, Kroog GS, Rodriguez-Lorenc K, Ma Q. Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study. Future Oncol. 2025 Mar;21(7):853-65. doi: 10.1080/14796694.2025.2461430

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024;20(28):2059-70. doi: 10.1080/14796694.2024.2348440

Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-63. doi: 10.2217/fon-2023-1064

Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193

Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573

Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315

Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531

Wise LA, Wesselink AK, Hatch EE, Rothman KJ, Mikkelsen EM, Sorensen HT, Mahalingaiah S. Marijuana use and fecundability in a North American preconception cohort study. J Epidemiol Community Health. 2018 Mar;72(3):208-15. doi: 10.1136/jech-2017-20975

Khan AM, Urquia M, Kornas k, Henry D, Cheng SY, Bornbaum C, Rosella LC. Socioeconomic gradients in all-cause, premature and avoidable mortality among immigrants and long-term residents using linked death records in Ontario, Canada. J Epidemiol Community Health. 2017 Jul;71(7):625-32. doi: 10.1136/jech-2016-208525

Hartley L, Girling A, Bowater R, Lilford R. A multistudy analysis investigating systematic differences in cardiovascular trial results between Europe and Asia. J Epidemiol Community Health. 2015 Apr;69(4):397-404. doi: 10.1136/jech-2013-203646

Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L. Green and black tea for the primary prevention of cardiovascular disease (CVD): a cochrane systematic review. Poster presented at the Society for Social Medicine conference at the Brighton and Sussex Medical School; September 2013. Brighton, United Kingdom. [abstract] J Epidemiol Community Health. 2013 Sep; 67(Suppl 1):A52-3. doi: 10.1136/jech-2013-203126.109

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Vrijheid M, Martinez D, Aguilera I, Ballester F, Basterrechea M, Esplugues A, Guxens M, Larranaga M, Lertxundi A, Mendez M, Murcia M, Marina LS, Villanueva CM, Sunyer J. Socioeconomic status and exposure to multiple environmental pollutants during pregnancy: evidence for environmental inequity? J Epidemiol Community Health. 2012 Feb;66(2):106-13. doi: 10.1136/jech.2010.117408

Mendez MA, Plana E, Guxens M, Foradada Morillo CM, Albareda RM, Garcia-Esteban R. Seafood consumption in pregnancy and infant size at birth: results from a prospective Spanish cohort. J Epidemiol Community Health. 2010 Mar;64(3):216-22.

Loughlin JE, Rothman KJ, Dreyer NA. Lymphatic and haematopoietic cancer mortality in a population attending school adjacent to styrene-butadiene facilities, 1963-1993. J Epidemiol Community Health. 1999 Jan 1;53(5):283-7.

Poole C, Rothman KJ. Our conscientious objection to the epidemiology wars. J Epidemiol Community Health. 1998 Oct 1;52(10):613-4.